MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

GLP-1 receptor agonists may reduce the time to first major adverse cardiovascular events in patients with type 2 diabetes.

• GLP-1 receptor agonists have been used to treat type 2 diabetes since the approval of exenatide in 2007.
• These compounds are designed for longer action, with some administered once daily or once weekly, improving glycemic control and body weight reduction.
• Clinical studies indicate that liraglutide, semaglutide, albiglutide, and dulaglutide are associated with a reduction in major adverse cardiovascular events in vulnerable patients.
• Liraglutide also appears to reduce both cardiovascular and all-cause mortality.
• The review discusses differences in pharmacokinetics, glucose-lowering potency, body weight effects, and cardiovascular outcomes among various GLP-1 receptor agonists.

AI simplified